The HIFU method is a minimally invasive and a precise method of prostate cancer removal that allows the patient to avoid surgery, resulting in a short hospitalization and less risk of complications (erectile dysfunction, urinary incontinence). This method does not preclude the application of further treatments.
The essence of this method is focusing an ultrasonic wave of high energy on a precisely defined area of the tumor. This action produces high heat effect in the tumor tissue, and consequently its destruction. In addition, bubbles of gas form in the cancer cell breaking down its structure.
The HIFU treatment lasts from 90 minutes to 2,5 hours (depending on the size of the tumor) under general anesthesia. The treatment is executed through natural routes of the body (without tissue cutting) by a probe in the rectum. Thanks to this method, HIFU is minimally invasive, resulting in a short hospitalization and less risk of complications and most importantly - allows the patient to avoid surgery.
It is worth mentioning that the HIFU method can be applied in cases of recurrence of prostate cancer in patients who have previously been treated with traditional methods such as radiation therapy or prostatectomy.
- Stage of cancer limited to the gland, T1, T2 N0 M0.
- Factor Gleason score ≤ 7.
- PSA <15 ng / ml (primary PSA measurement).
- Prostate volume ≤ 40 ml.
- Rectal mucosa without lesions, normal anatomy (rectal wall thickness <8 mm).
- No symptoms of urinary tract disease.
- Patients not eligible for radical prostatectomy.
- Patients not agreeing to radical surgery.
- Patients after ineffective brachytherapy.
- Patients with local recurrence after radiotherapy.
- Patients with local recurrence after radical prostatectomy
CRITERIA FOR QUALIFICATIONS FOR HIFU TREATMENT:
According to prof. Hashim U. Ahmed, Clinic of Urology, Imperial College of London
PSA ≤ 10 ng/ml
Malignancy of the cancer as a result of prostate biopsy - Gl.s. ≤ 7 (3 + 4)
Diameter of tumor <2.5 cm in magnetic resonance imaging (mpMRI)
Tumor present in one prostate lobe
PSA ≤ 15 ng/ml
Malignancy of the cancer as a result of prostate biopsy - Gl.s. ≤ 7
In magnetic resonance imaging - the tumor does not exceed the prostatic capsule
Additional criteria (cancer recurrence after radiotherapy):
Change visible in magnetic resonance imaging (mpMRI) confirmed in targeted biopsy PSA < 4 ng / ml
THE ULTIMATE DECISION FOR QUALIFING A PATIENT FOR THE HIFU TREATMENT IS MADE BY THE DOCTOR OR THE SPECIALIST OF THE EUROPEAN HEALTH CENTER OTWOCK.
Więcej informacji oraz rejestracja:
TEL: 22 7103300
TVP ,,Po prostu zdrowie": HIFU
SonaCare - SonaBlate
HIFU (High Intensity Focused Ultrasound)
Producent: SonaCare Medical, USA